The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification.

Autor: Shi, Chaoji1,2,3,4 (AUTHOR), Ju, Houyu1,2,3 (AUTHOR), Zhou, Rong1,2,3 (AUTHOR), Xu, Shengming1,2,3 (AUTHOR), Wu, Yunteng1,2,3 (AUTHOR), Gu, Ziyue1,2,3 (AUTHOR), Wang, Ying5 (AUTHOR), Chen, Wanling2,3 (AUTHOR), Huang, Xinyi2,3 (AUTHOR), Han, Yong1,2,3 (AUTHOR), Sun, Shuyang1,2,3 (AUTHOR), Li, Chuwen1,2,3 (AUTHOR), Wang, Min2,3,6 (AUTHOR), Zhou, Guoyu1,2,3 (AUTHOR), Zhang, Zhiyuan1,2,3,4 (AUTHOR) Zhiyuan.Zhang@sh9hospital.org.cn, Li, Jiang2,3,6 (AUTHOR) lijiang182000@126.com, Ren, Guoxin1,2,3 (AUTHOR) renguoxincn@sina.com
Zdroj: BMC Medicine. 5/29/2024, Vol. 22 Issue 1, p1-12. 12p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje